Full profile
| Also known as | L-alpha-glycerylphosphorylcholine, Choline alphoscerate, α-GPC |
|---|---|
| Best for | Choline delivery where a rationale exists · A comparison point against citicoline · Mostly studied in aging/impaired cognition, not healthy adults |
| Evidence grade | Grade C — Limited — early or small human trials |
| Studied dose range | 300–600 mg/day in studies; dose-conscious given the safety discussion. |
| Time to effect | Some acute choline-availability effects; cognition studies run over weeks. |
| Best form | Alpha-GPC (often a moisture-controlled branded form). For a healthy-adult cognition product, citicoline is the more defensible choline source. |
| Food sources | Supplemental form; dietary choline: eggs, liver, soybeans, meat |
Evidence, honestly graded
Most positive cognition trials are in dementia or post-stroke recovery populations, with sparse healthy-adult data. The key honest caveat is Lee et al. 2021 (JAMA Network Open), a South Korean cohort of roughly 12 million adults aged 50 and older, which found alpha-GPC use associated with a dose-responsive ~43% higher 10-year stroke risk (adjusted HR ≈1.43) — an association that persisted in a 4-year lag analysis meant to rule out reverse causation. A 2025 Korean cohort study did not fully replicate the association; both studies are observational, so this is a safety signal, not proven causation, but it's large and holds the grade down regardless of the efficacy data. Citicoline has cleaner healthy-adult attention data and no comparable signal.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
Side effects
- Headache
- Heartburn or GI upset
- Dizziness
- Insomnia at higher doses
Who should avoid it or check first
- Personal or strong family history of stroke or high cardiovascular risk (given the observational signal), without clinician review
- Pregnant or breastfeeding without clinician guidance
Interactions
- Theoretically additive with cholinergic drugs (e.g. cholinesterase inhibitors) — clinician review
- Consider cardiovascular context for higher-risk individuals
Stacks well with
- L-Theanine
- Bacopa Monnieri
Use caution stacking with
- Citicoline (redundant — do not stack two high-dose choline sources without rationale)
- Other high-dose choline donors
What to look for on a label
- State the choline delivered and avoid disease/treatment framing — alpha-GPC's better-studied populations are impaired, not healthy adults.
- Choline sources map to Health Canada's Cognitive Function Products monograph pathway, but the observational stroke association means a conservative brand should favour citicoline or carry a cautious, non-overreaching claim; do not present alpha-GPC as cardiovascular-safe-confirmed.
References
- Lee 2021, JAMA Network Open — alpha-GPC and 10-year stroke risk. South Korean cohort of ~12 million adults 50+; alpha-GPC use associated with a dose-responsive ~43% higher 10-year stroke risk (adjusted HR ≈1.43), persisting after a 4-year lag analysis — association, not proven causation. PMID 34817582; doi:10.1001/jamanetworkopen.2021.36008. Educational.
- 2025 Korean cohort study — partial non-replication. A subsequent Korean cohort analysis did not fully replicate the Lee 2021 stroke association. Both studies are observational; noted here so the safety discussion isn't one-sided. Educational, not a product claim.
- Health Canada NNHPD Cognitive Function Products monograph. Choline-type cognition-claim pathway; confirm alpha-GPC eligibility and claim wording against live monograph text. webprod.hc-sc.gc.ca/nhpid-bdipsn.
Primary citations for some entries above are still being compiled; those without a linked identifier are editorial summaries of the wider literature.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
See how Alpha-GPC compares on grade, dose, and goal in the Evidence Explorer.
